News | March 03, 2024
Briefs: SMS Pharmaceuticals and Vimta Labs
EDQM conducts GMP inspection of SMS Pharmaceuticals’ API facility
EDQM conducts GMP inspection of SMS Pharmaceuticals’ API facility
Clinical findings support the safety and efficacy of BMND08 at a maximum dosage of 12mg
The National One Health Mission will help India to achieve integrated disease control and pandemic preparedness
Cipla completes transfer of Generics Business Undertaking
The agreement licenses the company to launch in the United States, in February 2025, once approved by the U.S. FDA
Highlighting fully integrated organization, robust portfolio, and strategic priorities to drive long-term sustainable growth
BHL will undertake the development and supply of these molecules
The objective of GCMC is well aligned to WHO’s call to action and India’s National Biotechnology Development Strategy
_in_Mizushima,_Japan_256_384.jpg)
Contributing to lower risk of potentially carcinogenic nitrosamine impurities in pharmaceuticals
Survodutide has potential to become best-in-class treatment for metabolic dysfunction-associated steatohepatitis
Subscribe To Our Newsletter & Stay Updated
